Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 5/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14103319 | 0.78 | KDM1A (0.36) | SCN9AHDAC4KDM1A | |
| SCHEMBL27704919 | 0.77 | TDP1 (0.34) | SCN9ASCN5A | |
| SCHEMBL6382335 | 0.77 | SCN9A (0.31) | SCN9ASCN5A | |
| SCHEMBL13561 | 0.77 | SCN9A (0.33) | SCN9ASCN5AAURKATPX2 | |
| SCHEMBL6885111 | 0.75 | EPHX2 (0.37) | HDAC4 | |
| SCHEMBL28211761 | 0.74 | MCL1 (0.37) | KDM1A | |
| SCHEMBL22090484 | 0.73 | SCN5A (0.31) | SCN9ASCN5A | |
| SCHEMBL19268285 | 0.73 | SCN9A (0.32) | SCN9ASCN5A | |
| SCHEMBL16235740 | 0.73 | SCN9A (0.32) | SCN9ASCN5A | |
| SCHEMBL1478997 | 0.72 | LMNA (0.44) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023121939-A1 | SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-06-29 | — | — | WO | disclosed |
| US-11021493-B2 | 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use | AMGEN INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200231601-A1 | 1,4-THIAZINE DIOXIDE AND 1,2,4-THIADIAZINE DIOXIDE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2020-07-23 | — | — | US | disclosed |
| EP-3555086-A1 | 1,4-THIAZINE DIOXIDE AND 1,2,4-THIADIAZINE DIOXIDE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2019-10-23 | — | — | EP | disclosed |
| EP-2780026-B1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-23 | — | — | EP | disclosed |
| WO-2018112094-A1 | 1,4-THIAZINE DIOXIDE AND 1,2,4-THIADIAZINE DIOXIDE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| US-9328138-B2 | HCV NS3 protease inhibitors | MSD ITALIA S.R.L. (IT) | 2016-05-03 | — | — | US | disclosed |
| EP-2780026-A2 | HCV NS3 PROTEASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-09-24 | — | — | EP | disclosed |
| CN-103732613-A | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2014-04-16 | — | — | CN | disclosed |
| WO-2013074386-A2 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-05-23 | — | — | WO | disclosed |
| CN-101568336-B | Use of macrocyclic peptides for the preparation of hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2012-07-04 | — | — | CN | disclosed |
| CN-101568543-B | Macrocyclic peptides as hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2012-06-06 | — | — | CN | disclosed |
| US-20100204159-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-08-12 | — | — | US | disclosed |
| CN-101568336-A | Macrocyclic peptides as hepatitis C virus inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2009-10-28 | — | — | CN | disclosed |
| CN-101568543-A | Macrocyclic peptides as hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2009-10-28 | — | — | CN | disclosed |
| EP-2066688-A2 | MACROCYCLIC HCV INHIBITORS AND THEIR USES | Novartis AG (CH) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008033389-A2 | MACROCYCLIC HCV INHIBITORS AND THEIR USES | NOVARTIS AG (CH) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200231601-A1 | 1,4-THIAZINE DIOXIDE AND 1,2,4-THIADIAZINE DIOXIDE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | BACE1, BACE2, APP | SCN9A 3099/4885SCN5A 1241/4885HDAC4 2446/4885 |
| US-11021493-B2 | 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use | BACE1, BACE2, APP | SCN9A 3099/4885SCN5A 1241/4885HDAC4 2446/4885 |
| US-20100204159-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | SCN9A 3590/4885SCN5A 3088/4885HDAC4 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.